Telomir Pharmaceuticals presents preclinical data for Telomir-1

Telomir Pharmaceuticals announced that Telomir, alongside its partner Frontage Laboratories, presented a scientific poster at the National University Health System of Singapore Centre for Healthy Longevity Conference 2024 with data showing the effect of Telomir-1 on telomere length in three human cell lines: MRC-5 fetal lung fibroblasts, human umbilical endothelial cells, and mesenchymal stem cells. The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking. Danielle R. Baker, Ph.D., of Frontage Laboratories, presented the poster, titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains,” at the conference, which took place in Singapore, on February 29th and March 1st. The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.